May 2nd 2022
There was a continued trend toward improvement of overall survival with omidubicel at 73% compared with UCBT at 60%.
April 27th 2022
The analysis of data from ZUMA-7 demonstrated significant efficacy for axi-cel over second-line standard treatment.
April 26th 2022
Tisa-cel was associated with a more favorable safety profile in the analysis.
April 25th 2022
In this population, median progression-free survival was nearly 40 months.
KUR-502 elicited promising response rates for patients with relapsed or refractory B-cell malignancies in a phase 1 study.
The treatment seeks to improve immune reconstitution and graft-versus-leukemia immune response without increasing the risk of GvHD in children and young adults with hematologic malignancies.
Preliminary findings from the phase 1 clinical trial demonstrate good cell persistence and expansion in vivo.
The real-world data support the recently published results from a phase 3 study, which showed most patients achieved transfusion independence.
The greatest improvements were seen in the Pain, Fatigue, and Physical Functioning domains.
In 37 evaluable patients, the objective response rate in the study was 89% (95% CI, 75%-97%) with complete responses in 78%.